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Nothing to disclose 
Objectives 
 
 Describe current recommendations regarding influenza 
vaccination for individuals who report an egg allergy 
 
 Familiarize oneself with the new treatment options for 
hereditary angioedema 
 
 Identify the role for food allergy testing in patients with 
eosinophilic esophagitis (EoE) 
 
Case 1 
HPI: 20 year old male presents to establish care and for 
refill of his injectable epinephrine. Doing well and has no 
complaints. Has avoided eggs and has not had to use his 
injectable epinephrine. Seen by an Allergist years ago. 
Reaction to egg during childhood consisted of urticaria and 
breathing problems.   
 PMH: egg allergy, allergic rhinitis, no surgeries 
 ALL: NKDA 
MEDS: injectable epinephrine PRN, fluticasone nasal spray  
 FH: father with CAD, HTN  
 SH: nonsmoker, college sophomore 
 ROS: all negative 
 PE: all normal 
Case 1 
 Assessment/plan: 
 1. Egg Allergy 
o Continue avoidance 
o Refill of injectable epinephrine 
o ?Allergy evaluation 
 2. Allergic rhinitis 
o Refill fluticasone 
 3. Routine health maintenance 
o ?Recommend influenza vaccine 
What is your influenza vaccine recommendation? 
A. No vaccine 
B. Inactivated 
C. Live-attenuated 
D.Recombinant 
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J Allergy Clin Immunol. 2011 Jun;127(6):1629-32.,  
Influenza 
~294,128 hospitalizations yearly in the US (21,156 <5 yrs) 
 Average yearly deaths 23,607 (124 children)  
 
 Could these have been prevented with influenza vaccine 
o Grown in embryonated chicken eggs 
o ?potential allergic reaction to ovalbumin (egg protein) in egg 
allergic individuals (0.12-3.6% of the population) 
o Studies to date suggest risk low 
• included patients with histories of anaphylaxis to egg (currently about 
13% of the proven egg allergy population studied) 
J Allergy Clin Immunol. 2012 Jul;130(1):25-43.  
J Allergy Clin Immunol. 2012 Jul;130(1):25-43.  
Published studies (1998, others since 2010) 
>1600 egg allergic patients (mostly children) vaccinated 
without serious reactions 
 0-6.3% skin reactions (urticaria) 
 0-4.8% mild respiratory or gastrointestinal symptoms 
 0 hypotension 
 0 treatments with epinephrine 
 Controls experienced similar rates of reactions  
One study included 3640 individuals with reported but 
not proven egg allergy 
o 1.2% skin reaction 
o 0.7% respiratory reactions including 2 which were treated with 
injectable epinephrine (although authors concluded these 
symptoms were not anaphylaxis) 
 
J Allergy Clin Immunol. 2012 Jul;130(1):25-43.  
J Allergy Clin Immunol. 2012 Jul;130(1):25-43.  
Summary 
 Patients with egg allergy should receive the vaccine in a 
medical setting  
Only hives can receive in primary care provider’s office 
and wait 30 minutes 
 If severe symptoms refer to Allergy/Immunology physician 
 Number of patients studied to date (~5000) cannot exclude the possibility 
of a rare severe reaction  
 All influenza vaccines in the US contain low ovalbumin 
o 0.7 μl/0.5mL dose 
 Intranasal vaccine does contain albumin and has not been 
studied therefore egg allergic individuals should not be 
given this 

New in 2013 trivalent recombinant vaccine  
 FluBlok 
o Expression of proteins in insect cells using recombinant baculovirus 
 Developed due to: 
o Specialized facilities 
o Decreased ability to scale up egg production rapidly  
o Poultry potentially vulnerable to influenza viruses 
o Time consuming adaption of candidate vaccine viruses for high 
yield growth 
 Low rates of local and systemic reactions 
o Systemic reactions similar to placebo 
 Safe, immunogenic and effective in the prevention 
 Approved in >18 years (18-49) 
 SAFE BUT LESS IMMUNOGENIC IN CHILDREN 
$$$$ (to patient) 
 Fluzone 
o $30 
High dose Fluzone  
o $40   
 Flumist  
o $35   
  Flublok 
o $50 
 
Case 2 
HPI: 21 year old male presents for treatment of hereditary 
angioedema (HAE) dx at 2y/o. Weekly episodes (↑ severity 
frequency). No ICU admissions but numerous emergency 
department visits. Does not take danazol due to concern 
of long term side affects. Lost to follow up many years.  
 PMH: HAE, depression/anxiety 
 ALL: NKDA 
MEDS: danazol  
 FH: mother and brother with HAE  
 SH: unemployed, lives with mother 
 ROS: negative 
 PE: normal 
 Labs: 
 
C4 complement 11 (16-47 mg/dL) 
C1-inhitor functional assay 32 (>=40%) 
C1-inhibitor protein 9 (21-39 mg/dL) 
C1q 6.7 (5.0-8.6 mg/dL) 
Which is the most appropriate prophylactic therapy? 
A. Attenuated 
androgens 
B. Fresh frozen 
plasma 
C. Antifibrinolytic 
agents 
D.C-1 inhibitor 
concentrate 
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Hereditary Angioedema (HAE) 
 Autosomal dominant 
 Presents in late childhood or adolescence 
 Prevalence 
o 1:10,000 to 1:150,000 
o Equal among races; Women = Men 
 Attacks build in severity over 12-36 hours 
 Resolution: 24-72 hours 
 Unpredictable, waxing/waning, delayed diagnosis 
 Significant morbidity 
 Treatment: 
o Response is variable 
o Antihistamines, glucocorticoids, or epinephrine are ineffective 
 
HAE Morbidity 
Web-based survey of 457 HAE patients found: 
o 100% felt disease prevented them from advancing in school 
o 69% felt unable to consider certain jobs 
o 58% affected career advancement 
 Impact of last HAE attack: 
o 51% missed ≥1 work day 
o 44% missed ≥1 school day 
o 59% missed ≥1 leisure day 
 
 Attacks result in 20-100 days of incapacitation annually 
o Approximately 15,000 to 30,000 ER visits/yr 
 
 Unpredictability of attacks causes significant psychological 
burden 
Castaldo AJ, et al. Ann Allergy Asthma Immunol. 2009;102:A92 
Moore GP, et al. Ann Emergency Med. 1988;133:1082-1086 
Santos C, et al. Ann Allergy Asthma Immunol .2009;102:A38 
Pathophysiology 
Mutation of C1 esterase inhibitor gene (C1-INH) 
Inhibition of the kallikrein-kinin system 
Increased bradykinin production 
Vasodilation and increased permeability 
Localized subcutaneous or submucosal swelling 
Diagnosis Criteria 
 Clinical criteria 
o Recurrent angioedema that is self-limiting, non-pitting, non-
pruritic, non-erythematous 
o Edema usually lasts for more than 12 h with no major urticaria 
o Family history of hereditary angioedema 
 Laboratory criteria 
o C1 inhibitor <50% of normal values obtained on two separate 
occasions after first year of age 
o Functional levels of C1 inhibitor <50% (chromogenic assay) or 
<84% (ELISA assay; local normal ranges might vary) of normal 
values obtained on two separate occasions after first year of age) 
o Mutation in C1-inhibitor gene that modifies protein synthesis or 
function 
 
* Need one clinical and one laboratory criterion 
Common HAE Triggers 
Trauma Menstruation 
Infection 
Stress 
Medications 
Angioedema 
 
Angioedema 
attack 

HAE Treatment: U.S. Timeline 
Prevention: Androgen 
derivatives, anti-fibrinolytics 
 
Acute: FFP, supportive care 
C1 Esterase 
Inhibitor (Cinryze) 
PREVENTION 
C1 Esterase 
Inhibitor (Berinert) 
ACUTE 
Dec  
2009 
Oct 
2008 
Ecallantide 
(Kalbitor) 
Icatibant 
(Firazyr) 
Aug 
2011 Oct 
2009 
Prophylactic Treatment of HAE 
Prophylaxis typically used for: 
o Short-term: Planned exposure to a trigger situation 
• Dental work 
• Invasive medical procedures 
• Surgery 
o Long-term: Frequent attacks (i.e. >2 attacks/month or 
several times per year causing decreased QOL) 
Prophylaxis options 
o Androgen derivatives (Danazol) 
o Antifibrinolytic agents 
o Nanofiltered C1 inhibitor concentrate (Cinryze®) 
Androgen Derivatives: Danazol 
 Androgen derivatives: 17-α-alkylated androgen  
o Danazol 
o Stanazol – compounded only 
• Average dose 2mg daily 
o Oxandrolone 
• Approved for pediatric use 
Mechanism of action 
o Thought to increase hepatic synthesis of C1-INH 
 Pharmacokinetics of danazol 
o Onset: Slow ~4 weeks 
o Time to peak: 2 hours  
o Half-life: 4.5 hours (variable) 
 
Danazol (cont.) 
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Agostoni et al, Lancet. 1978 
Effects on 
C1-Inhibitor 
Danazol (cont.) 
 Adverse effects 
o Virilization 
o Weight gain 
o Menstrual disorders/amenorrhea 
o Psychological disorders 
o Headache 
o Myalgia 
o Acne 
o Increased sweating 
o Diminished libido 
o Hepatocellular adenoma 
o Hirsutism 
o Hyperlipidemia 
 
 Frequency and severity of adverse effects with danazol 
increase with dosage strength and duration of therapy 
 
 
Danazol: Hepatocellular Adenomas 
Hepatocellular adenomas have been associated with long-
term (>10 years) danazol prophylaxis 
o In some of these cases, the adenomas regressed 18-24 months after 
discontinuation of danazol 
 
 Fatal hepatic failure has also been reported 
 
 Therefore, periodic liver function monitoring has been 
strongly advocated (i.e. annually) 
 
Gompels MM et al., Clin Exp Immunol. 2005 
Crampon D et al., J Hepatol. 1998 
Bork K et al., J Hepatol. 2002 
Danazol: Dosing 
Not for acute treatment, several days for efficacy 
 Short-term prophylaxis: 
o 200mg TID for 5-10 days before event, may continue after for a 
few days 
 Long-term prophylaxis (if >1 attack every 3 months): 
o Use the lowest effective dose  
o Usual dose: 200mg/day (Range 100mg every 3 days to 600mg 
daily) 
o Options  
• High dose of 400-600 mg daily, then taper down every 2-4 weeks to 
a dose that achieves symptomatic control OR 
• Start a low dose of 50 mg daily, then taper up every 2-4 weeks to an 
effective dose  
 
 Cost: $55.99 for 30 capsules (50 mg) 
Danazol: Efficacy in Long-term Prophylaxis 
Cumulative Freedom from  
HAE Attacks at Varying Dosages 
98% 
>1% 
Placebo   Danazol 
Danazol Dosage (mg/d) 
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Frank M. Immunol Allergy Clin N Am. 2006 
Gelfand JA, et al. N Engl J Med. 1976 
Antifibrinolytic Agents 
 Aminocaproic acid and tranexamic acid 
Not for acute treatment, several days for efficacy 
 Possibly not as effective as androgen derivatives 
 Better safety than androgens in pregnancy and children 
Most common side effects 
o Nausea and diarrhea 
o Vertigo 
o Postural hypotension 
o Fatigue 
o Muscle cramps/weakness (increased muscle enzyme concentrations) 
o Risk of vascular thrombosis 
o Teratogenicity? 
 
 
Antifibrinolytic Agents (cont.) 
Drug Name Usual Prophylactic Adult Dose (Range) 
Usual Prophylactic  
Pediatric Dose (Range) 
Aminocaproic acid 2g TID 
(1g BID – 4g TID) 
0.05 g/kg BID  
(0.025 g/kg BID–0.1 g/kg BID) 
Tranexamic acid 1g BID 
(0.25g BID – 1.5g TID) 
20 mg/kg BID 
(10 mg/kg BID–25 mg/kg TID) 
Zuraw BL. N Engl J Med. 2008;359:1027-36. 
*NOT FDA Approved for HAE in either adults or children 
C1-Inhibitor Concentrate: Cinryze® 
Nanofiltered, highly purified human C1 esterase inhibitor 
 First C1 esterase inhibitor therapy for routine PREVENTION 
o FDA approved in October 2008 (adults and adolescents) 
o UIHC formulary for prevention (past agent for acute) 
 Pharmacokinetics 
o Onset of action: ~1 hour; Peak: ~4 hours; Half-life: 56 hours 
 Adverse effects 
o Headache, upper respiratory infections, sinusitis, rash, DVT/TIA, 
MI, thrombosis 
 Dosing: 1000 units IV infusion every 3-4 days 
o 1 mL/ minute over 10 minutes at room temperature 
o May also give 500 - 1500 units <24 hrs                                            
(best 1 hour) prior to provoking event  
 Cost:  
o ~$2,900/500 units (Dose = $5,800) 
 
 CHANGE Trial: C1-inhibitor in Hereditary Angioedema 
Nanofiltration Generation evaluating Efficacy 
 
N=22 patients with at least 2 HAE attacks/month 
 
 24-week double-blind, placebo-controlled cross-over study 
 
 Randomized to 12 weeks of C1-INH 1000 units or placebo 
o Prophylactic infusions every 3-4 days 
o After 12 weeks patients switched treatment arms 
 
C1-Inhibitor Concentrate: Cinryze® (cont.) 
Zuraw et al. N Engl J Med 2010;363:513-22. 
CHANGE Trial (cont.) 
Zuraw et al. N Engl J Med 2010;363:513-22. 
 C1 inhibitor concentrate had 
significant reductions vs. 
placebo in the following: 
o Severity of attacks 
• Score: 1.3 vs 1.9 
o Duration of attacks 
• 2.1 vs 3.4 days 
o Need for open-label rescue 
therapy  
• N=11 vs N=22 
o Total number of days with 
swelling 
• 10 vs 30 days 
12.7 
6.3 
P <0.001 
Acute Treatment for HAE 
 Purified C1 inhibitor concentrate (Berinert®) 
o Cinryze studied but not FDA approved 
 Ecallantide (Kalbitor®) 
 Icatibant (Firazyr®) 
Others 
o FFP 
• May worsen symptoms due to contact-system proteins 
o Supportive therapy during acute attacks 
• Airway management  
• Pain management, opioids often required 
• Anti-emetics for nausea/vomiting 
• IV fluids 
 *Corticosteroids, antihistamines, and epinephrine not effective in aborting 
acute attacks and should generally not be given for HAE 
 
Purified C1 Inhibitor Concentrate: Berinert® 
 Purified human C1-INH from plasma donors 
o FDA Approved for ACUTE treatment abdominal/facial attacks in 
adults and adolescents - October 2009 
o UIHC Formulary agent for Acute Attacks (Feb 2012) 
 Pharmacokinetics 
o Onset: ~1 hr; Time to peak: ~4 hrs; Half-life: 22 hours 
 Adverse effects 
o Headache, abdominal pain, nausea, muscle spasm, pain, diarrhea, 
vomiting, injection site reaction, fever, chills, hypersensitivity 
 Dose: 20 units/kg IV (~4 ml/min), repeat after 30 min if needed 
o Ex: 50 kg = 1000 units, 75 kg = 1500 units,                               
100 kg = 2000 units, 125 kg = 2500 units 
o Consider rounding dose up 
 Cost: ~$1,400 for 500 units 
 
Purified C1 Inhibitor Concentrate: Berinert® (cont.)  
 IMPACT Trial: International Multicenter Prospective 
Angioedema C1-INH Trial 
 
 Randomized, double-blind, placebo-controlled study 
 125 HAE patients enrolled (45 centers, 15 countries) 
o Acute facial or abdominal HAE attacks 
o Age range: 6-72 
 C1 inhibitor concentrate (Berinert) 10 U/kg and 20 U/kg 
vs. placebo within 5 hours of attack 
 Rescue dose: if no relief in 4 hrs gave Berinert 20 U/kg for placebo group, 
10 U/kg in 10 U/kg group, or placebo in 20 U/kg group 
 Primary endpoint: time to onset of symptom relief 
 
Craig TJ, et al. J Allergy Clin Immunol. 2009;124:801-8. 
IMPACT Trial (cont.) 
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Placebo 
n=42 
Berinert 
10 U/kg 
n=39 
Berinert 
20 U/kg 
n=43 
Craig TJ, et al. J Allergy Clin Immunol. 2009;124:801-8. 
Berinert 
Craig TJ, et al. J Allergy Clin Immunol. 2009;124:801-8. 
IMPACT Trial (cont.) 
Ecallantide: Kalbitor® 
Highly selective recombinant kallikrein inhibitor 
o FDA Approved Dec 2009 (>16 yo) 
 Pharmacokinetics 
o Onset: 30 min - 4 hrs; Time to peak: ~2-3 hrs; Half-life: ~2 hrs 
 
 
 
Ecallantide 
Ecallantide: Kalbitor® (cont.) 
 Administration 
o Subcutaneous injection in abdomen, upper arm, or thigh 
o Must be administered by a healthcare worker  
 Dosing: 30 mg per dose 
o Administered as three 10mg/mL doses 
o Repeat dose may be given within 24 hours 
 Adverse effects 
o Headache (8%), nausea (5%), diarrhea (4%), fever (4%), 
injection site reaction (3%) 
 Black box warning: Anaphylaxis 
o 5 of 187 patients (3%) 
o Typically appears within 1 hour 
 Cost: $9,540 per 30 mg treatment 
STUDY EDEMA31 
(N=72) 
EDEMA42 
(N=96) 
Inclusion Age >10 
<8hrs of moderate-severe^ attack 
Age >10 
<8hrs of moderate-severe attack 
Treatment Ecallantide 30mg SC vs 
Placebo 
Ecallantide 30mg SC vs 
Placebo 
Median patient-reported 
treatment outcome score* 
at 4 hours  
50.0 vs 0.00 
(P=0.004) 
53.4 vs 8.1 
(P=0.003) 
Median change in 
symptom severity score at 
4 hours from baseline 
-1.00 vs -0.50 
(P=0.14) 
-0.8 vs -0.4  
(P=0.01) 
Ecallantide: Kalbitor® - EDEMA Studies 
1. Cicardi M, et al. NEJM 2010;363:523-31. 
2. Levy RJ, et al. Ann Allergy Asthma Immunol. 2010;104:523-9. 
 Phase III, double-blind, placebo-controlled trials 
^Moderate: Intervention highly desirable, impedes ADLs; Severe: necessitates treatment, inability to do ADLS 
*TOS: 100=sig improvement, 50=improvement, 0=same, -50=worsening, -100 sig worsening 
Icatibant: Firazyr® 
 Selective Bradykinin β2 Receptor Antagonist 
o FDA Approved August 2011 (>18 yo) 
 Pharmacokinetics: 
o Onset: ~2 hours; Time to peak: 45 minutes; Half-life: 1-2 hours 
 
 
Icatibant 
Icatibant: Firazyr® (cont.) 
 Administration 
o Subcutaneously into abdomen 
o May be self-administered at home 
 Dosing 
o Inject 30 mg over ≥ 30 seconds 
o May repeat every 6 hours; max of 3 doses/ 24 hours 
 Adverse Effects: 
o Injection site reaction (97%), fever (4%), elevated transaminase 
levels (4%), dizziness (3%) 
 Cost: $2500 for 30 mg dose 
 
 
STUDY FAST-11 
(N=56) 
FAST-21 
(N=74) 
FAST-32 
(N=88) 
Inclusion Age >18 
<6hrs of mod-severe 
cutaneous/abd attack 
Age >18 
<6hrs of mod-severe 
cutaneous/abd attack 
Age >18 
<6hrs of moderate-severe 
cutaneous attack OR 
<12hrs abdominal attack 
Treatment Icatibant 30mg SC 
vs Placebo 
Icatibant 30mg SC  
vs Tranexamic acid 
Icatibant 30mg SC  
vs Placebo 
Median time to 
clinically significant 
relief of index symp. 
2.5 vs 4.6 hrs 
(P=0.14) 
2.0 vs 12.0 hrs 
(P<0.001) 
1.5 vs 18.5 hrs 
(P<0.001) 
Median patient-
assessed time to 
improvement  
0.8 vs 16.9 hrs 
(P<0.001) 
0.8 vs 7.9 hrs 
(P<0.001) 
2.0 vs 19.8 hrs*  
(*50% improvement) 
(P<0.001) 
Median physician-
assessed time to 
improvement 
1.0 vs 5.7 hrs 
(P<0.001) 
1.5 vs 18.5 hrs 
(P<0.001) 
 
NA 
Icatibant: Firazyr® - FAST Studies 
1. Cicardi M, et al. NEJM. 2010;363:532-41. 
2. Lumry WR, et al. Ann Allergy Asthma Immunol. 2011;107:529-37. 
Summary: Acute HAE Treatment 
Acute HAE Attacks: Emerging Therapy 
 Recombinant Human C1-INH (Conestat alfa - Rhucin™) 
o From the milk of transgenic female rabbits 
o DNA contains an extra bovine milk-specific promoter sequence 
(alpha-S1 casein) functionally linked to the gene encoding human 
C1 inhibitor 
o Induces production of rhC1INH in milk at levels of 12 g/L  
 Phase I trial of 12 subjects results 
o Reported no adverse events 
o Showed no evidence of immune rejection 
o Demonstrated evidence of systemic availability and activity  
Ongoing phase II/III trials in patients age 12 or older 
 Dosing: <84 kg = 50 U/kg; >84kg = 4200 U in adults 
 
 
Summary 
 Recurrent episodes of non-pruritic swelling without hives 
warrants further evaluation for hereditary angioedema 
Newer therapies offer patients significant hope 
 1st line prevention OR acute attacks: C1-inhibitor 
 2nd line for acute attacks: ecallantide or icatibant 
 Considerations for choice of therapy: 
o Route of administration 
o Patient preference 
o Efficacy 
o Safety and tolerability 
o Cost 
 
 
Case 3 
HPI: 35 year old male seen in consultation from 
gastroenterology for evaluation of eosinophilic esophagitis 
(EoE) Recently had an EGD for impaction. History of 
dysphagia the prior 3-5 years.  
 PMH: Allergic rhinitis 
 ALL: NKDA 
MEDS: omeprazole 20 mg daily 
 FH: brother with asthma 
 SH: degree in finance and law 
 PE: normal 
 Review of epic revealed 40 – 60 eosinophils/hpf on distal 
esophageal biopsy “some” in proximal 
 Labs: no eosinophilia, mildly elevated IgE  
 
What is the next best step? 
A. Watch and wait 
B. Order IgG to foods 
C. Aeroallergen testing 
D. Skin prick test to foods 
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Eosinophilic esophagitis 
 Esophageal eosinophilia 
 Emerging disease 
o 1977 (Dobbins, et al.) 
Male predilection 
 Affects both children and adults 
o Adults commonly present in the third decade 
 Symptoms of heartburn, dysphagia, food impaction, CP 
o Children present with feeding difficulties, FTT, food aversion, 
regurgitation, abdominal pain, emesis, GERD symptoms 
 Current diagnostic criteria 
o Symptoms 
o 15 eosinophils/hpf 
o Exclusion of other disorders 
Allergy Asthma Proc. 2012 May-Jun;33 Suppl 1:S88-90. 
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6 
 
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6 
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6 
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6 
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6 
Role for allergy 
 Aeroallergen sensitivity in majority of adults/older children 
o Role controversial 
o ?Seasonal pattern to diagnosis of EoE 
o May act directly causing allergic inflammation or systemically 
 Rare history of food-induced anaphylaxis 
 Strictures may case dysphagia and impaction therefore 
identification of food triggers difficult 
 ?delayed reaction to foods 
o Patch testing not currently validated or standardized 
 Food allergy testing (specific IgE)  
o Guide food elimination/reintroduction 
o Clinical utility for identification of triggers largely unknown 
o Adults have fewer positives to foods 
Case 3 
 Positive skin prick testing to the following aeroallergens: 
o Lamb’s quarter, ragweed, Russian thistle, Timothy, numerous trees 
 Positive skin prick testing to the following foods: 
o Almond, hazelnut, peanut, soybean, milk and eggs 
 Positive specific IgE: 
o Pork, soybean, egg, rice, almond, hazelnut, peanut (negative to milk) 
 IgE 900 IU/mL 
 Treatment 
o Swallowed fluticasone, 1-2 puffs daily; increased PPI 
o Elimination diet (rice, pork, boiled eggs, soy, dairy, nuts) 
• *not strictly avoiding 
 Repeat EGD: 
o No eosinophils in proximal esophagus, 20 Eos/hpf in distal 
 Asymptomatic 
 
 
 
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6 
Questions? 
